Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
05/2003
05/02/2003EP1305299A1 Cyclic polyamine compounds for cancer therapy
05/02/2003EP1305296A2 5-substituted pyrimidine derivatives of conformationally locked nucleoside analogues
05/02/2003EP1305295A1 Imidazole derivatives
05/02/2003EP1305294A2 Imidazolyl derivatives
05/02/2003EP1305293A1 Hexahydro-7-imino-1h-azepin-2-yl-hexanoic acid derivatives as inhibitors of inducible nitric oxide synthase
05/02/2003EP1305292A1 Biphenyl carboxamides
05/02/2003EP1305291A1 3-substituted isoquinolin-1-yl derivatives
05/02/2003EP1305290A1 Novel heteroaryl derivatives and the use thereof as pharmaceuticals
05/02/2003EP1305289A2 Novel heteroaryl derivatives and use thereof as anti-tumour agents
05/02/2003EP1305286A2 Cyclopentanoindoles, compositions containing such compounds and methods of treatment
05/02/2003EP1305285A1 N-substituted indoles useful in the treatment of diabetes
05/02/2003EP1305282A1 Pleuromutilin derivatives having antibacterial activity
05/02/2003EP1305274A2 Novel c-4 substituted retinoids
05/02/2003EP1305082A2 Carbamate compounds for use in preventing or treating neuropathic pain and cluster and migraine headache-associated pain
05/02/2003EP1305053A1 A medicinal aerosol formulation
05/02/2003EP1305051A2 Targeted delivery of cytotoxic drugs a) to activated lymphocytes in patients with transplanted organs, b) as radiosensitizers to cancer cells in patients undergoing radiation therapy, and c) in vitamin-binding proteins as drug carriers in the diagnosis and treatment of cancer
05/02/2003EP1305050A2 Improved oral dosage formulations
05/02/2003EP1305047A2 Non-peptide ccr1 receptor antagonists in combination with cyclosporin a for the treatment of heart transplant rejection
05/02/2003EP1305046A2 Regulators of ppardelta (beta) and their use in the treatment of obesity and insulin resistance
05/02/2003EP1305045A1 Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications
05/02/2003EP1305037A2 Anti-inflammatory medicament
05/02/2003EP1305036A2 Nutritional composition
05/02/2003EP1305035A1 Naadp analogues for modulating t-cell activity
05/02/2003EP1305034A2 Methods of producing weight loss and treatment of obesity
05/02/2003EP1305033A1 Pharmaceutical compositions containing tobramycin and xanthan gum
05/02/2003EP1305032A1 Compositions and methods of preventing or reducing the risk or incidence of skeletal injuries in horses
05/02/2003EP1305031A2 Combination preparations of 3-n-formylhydroxylaminopropyl phosphonic acid derivatives or 3-n-acetylhydroxylaminopropyl phosphonic acid derivatives combined with specific pharmaceutical active agents
05/02/2003EP1305030A1 USE OF 2$g(a)-METHYL-19-NOR-20(S)-1$g(a),25-DIHYDROXYVITAMIN D3 TO INCREASE BONE STRENGTH
05/02/2003EP1305029A1 Method of increasing sensitivity of mammography
05/02/2003EP1305028A2 Antimicrobial biaryl compounds
05/02/2003EP1305027A2 Use of an aldehyde 5-oxo-1,2,4-triazine hydrazide for the treatment of cancer
05/02/2003EP1305026A2 Barbituric acid analogs as therapeutic agents
05/02/2003EP1305025A1 Pharmaceutical composition comprising metformin and a 5-phenoxyalkyl-2,4-thiazolidinedione-type derivative
05/02/2003EP1305024A1 Method for treating fibrotic diseases or other indications ic
05/02/2003EP1305023A1 Use of selective adenosine a1 receptor agonists, antagonists and allosteric enhancers to manipulate angiogenesis
05/02/2003EP1305022A1 Processes for the purification of tocopherol and/or sterol compounds and compositions containing orthoborate ester mixtures
05/02/2003EP1305021A1 Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
05/02/2003EP1305020A2 Use of fibrates for the preparation of a medicament useful in the treatment of congestive heart failure
05/02/2003EP1305019A2 Immunomodulatory compounds
05/02/2003EP1305018A1 Method and compositions for prevention and/or treatment of diabetes and glucose modulation
05/02/2003EP1305017A1 Methods and compositions for the prevention and treatment of syndrome x
05/02/2003EP1305016A1 Use of n-oleoylethanolamine for treating psoriasis
05/02/2003EP1305015A1 Substituted styryl benzylsulfones for treating proliferative disorders
05/02/2003EP1305014A1 Method for the treatment of climacteric disorders in women during or after the menopause
05/02/2003EP1305013A1 Preparation with vascular protective and anti-oxidative effect and use thereof
05/02/2003EP1305012A2 A method for treating celiac disease
05/02/2003EP1305010A2 Dosage forms for treatment of oral mycoses
05/02/2003EP1305009A1 Cross-linked high amylose starch for use in controlled-release pharmaceutical formulations and processes for its manufacture
05/02/2003EP1305008A2 Improved forms of pharmaceutically active agents and method for manufacture thereof
05/02/2003EP1305007A2 Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
05/02/2003EP1305006A2 Dispersions for formulating slightly or poorly soluble active ingredients
05/02/2003EP1305003A2 Use of a combination of active substances containing bioquinones for the production of cosmetic or dermatological preparations
05/02/2003EP1304992A1 Topical gel delivery system
05/02/2003EP1223966B1 Use of gdnf for treating corneal defects
05/02/2003EP1223951A4 Method of preventing adhesions with absorbable polyoxaesters
05/02/2003EP1221939A4 Ortho ester lipids
05/02/2003EP1200064B1 Delivery system for oral care compositions comprising organosiloxane reins using a removable backing strip
05/02/2003EP1196167A4 Method of reducing neuronal injury or apoptosis
05/02/2003EP1194186B1 CARDIOACTIVE COMPOSITION COMPRISING L-CARNITINE AND ITS DERIVATIVES AND i CRATAEGUS /i EXTRACTS
05/02/2003EP1189611A4 Cancer therapy
05/02/2003EP1185516B1 Substituted phenylcyclohexane carboxylic acid amides that have an adenosine uptake inhibiting effect
05/02/2003EP1171111B1 Granulate with high content of l-carnitine or an alkanoyl l-carnitine, particularly suitable for the production of tablets by direct compression
05/02/2003EP1140115B1 Phospholipid complexes of proanthocyanidin a2 as antiatherosclerotic agents
05/02/2003EP1140061B1 Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
05/02/2003EP1128730B1 Antimicrobial composition comprising an oxidoreductase and an enhancing agent of the n-hydroxyanilide-type
05/02/2003EP1121375B1 High purity compound (7alpha,17alpha)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one
05/02/2003EP1121351A4 Preparation of (s)-2-amino-6,6-dimethoxyhexanoic acid methyl ester via novel dioxolanes
05/02/2003EP1119351B1 Use of catechol derivatives as proteinase inhibitors
05/02/2003EP1109538B1 Anti-inflammatory pharmaceutical formulations
05/02/2003EP1105388B1 N-substituted azabicycloheptane derivatives, production and use thereof
05/02/2003EP1105381B1 Dibenzothiophene compounds and methods of use thereof
05/02/2003EP1102536B1 Use of oxathiazolones as microbicides
05/02/2003EP1100796B1 Process for the preparation of a non-crystalline anhydrate form of paroxetine hydrochloride
05/02/2003EP1096933B1 Use of an inhibitor of cytochrome p450 optionally combined with an antifungal agent for treating mycoses
05/02/2003EP1093361B1 Plaster which contains steroids, and a method for the production and use thereof
05/02/2003EP1089712B1 Large porous particles emitted from an inhaler
05/02/2003EP1086103B1 Pyrido 2,3-b]indolizine derivatives and aza analogues thereof; crf 1 specific ligands
05/02/2003EP1070058B1 (4-arylsulfonylamino)-tetrahydropyran-4-carboxylic acid hydroxamides
05/02/2003EP1056704B1 Antitumor agents
05/02/2003EP1056475B1 Dendrimeric fullerene derivatives, method for producing same and their use as neuroprotectors
05/02/2003EP1056454B1 Use of macrolide compounds for treating glaucoma
05/02/2003EP1045846B1 Imidazole derivatives having an inhibitory activity for farnesyl transferase and process for preparation thereof
05/02/2003EP1037886B1 Triazine angiogenesis inhibitors
05/02/2003EP1036167B1 Nuclear targeting by means of streptococcal protein h
05/02/2003EP1035828B1 Topical compositions for regulating the oily/shiny appearance of skin
05/02/2003EP1032579B1 Carbohydrate derivatives
05/02/2003EP1025082B1 Novel vitamin d derivatives with cyclopropyl rings in the lateral chains, a method and intermediate products for the production thereof and the utilization thereof for producing medicaments
05/02/2003EP1021448B1 TRICYCLIC COMPOUNDS HAVING ACTIVITY AS Ras-FPT INHIBITORS
05/02/2003EP1021171B1 Delayed total release gastrointestinal drug delivery system
05/02/2003EP1019042B1 Anti-first-pass effect compounds
05/02/2003EP1015423B1 1,3-dihydroxy-20,20-dialkyl-vitamin d 3? analogs
05/02/2003EP1007014B1 Transdermal, hormone-delivering therapeutic system
05/02/2003EP1003557B1 New salts with beneficial organoleptic properties
05/02/2003EP1001813B1 Pharmaceutical formulations containing voriconazole
05/02/2003EP0999840B1 Use of a draflazine analogue for treating pain
05/02/2003EP0998272B1 Pharmaceutical composition for combination of piperidinoalkanol-decongestant
05/02/2003EP0993455B1 POLYMORPHS OF 8-CHLORO-6, 11-DIHYDRO-11- (4-PIPERIDYLIDENE) -5H-BENZO[5,6] CYCLOHEPTA[1,2-b]PYRIDINE
05/02/2003EP0988035B1 Caspases and apoptosis
05/02/2003EP0986396A4 Prion protein modulator factor (ppmf) and prion resistant animals
05/02/2003EP0984957B1 Novel form of s-omeprazole
1 ... 5481 5482 5483 5484 5485 5486 5487 5488 5489 5490 5491 5492 5493 5494 5495 5496 5497 5498 5499 5500 5501 ... 7860